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Investigating the outcome of the assessment at national transgender health service: 
Time to review the process? 
Abstract 
Background: Globally there is a lack of standardised assessment process prior to the initiation of 
physical interventions and consequently there is a discrepancy in this process among different 
transgender health services.  
Aim: The main objective of this study is to investigate the outcome of the assessment process at a 
national transgender health service.  
Method: The outcome of people assessed at a large national transgender health service in the UK 
during a two years period was categorised into: 1) recommendation for hormone treatment, or: 2) no 
recommendation for hormone treatment. In addition, 200 case-notes were reviewed in order to 
investigate the level of agreement between the two clinicians involved in the assessment process. 
Results: During the studied period a total of 617 people completed their assessment at the service. 
Following assessment 380 (61.6%) patients were recommended for hormone treatment and leaving 
237 (38.4%) patients requiring a longer assessment period or being discharged. The factors associated 
with being recommended for hormone treatment were: having socially transitioned, not smoking, 
having initiated cross-sex hormones prior to assessment, being older, and assigned male at birth. Out 
of the 200 case-notes reviewed, agreement between assessor 1 and 2 (3 months apart) was found in 
88 % (n= 176) of the cases.  
Discussion: Although the results of the study may not be generalizable to other international centres, 
questioning the assessment process and the role of the assessors is important to ensure treatment is 
offered in a timely and efficient manner. The findings from this study suggest that the inclusion of two 
assessors needs to be reviewed.  
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Investigating the outcome of the assessment at national transgender health service: 
Time to review the process? 
Introduction 
In the context of the high demand for transgender health services (de Vries, Krekels, T'Sjoen, Ålgars, 
& Mattila, 2015) and the predicted increase in demand (Arcelus et al., 2015); in addition to the 
prevalence of mental health problems in treatment seeking transgender people when transgender 
healthcare cannot be accessed (e.g., Arcelus, Claes, Witcomb, Marshall, & Bouman, 2016; Bouman et 
al., 2016; Dhejne, Van Vlerken, Heylens, & Arcelus, 2016) and the associated costs to health services 
(Padula, Heru, & Campbell, 2016); timely access to gender affirmative treatment (whether cross sex 
hormones and/or surgeries) presents a major healthcare challenge (Joseph, Cliffe, Hillyard, & Majeed, 
2017; Reisner et al., 2016). However there is growing evidence that has found gender affirming 
interventions to increase well-being (e.g., decrease in levels of anxiety and depression; Bouman et al., 
2016; Dhejne et al., 2016; Millet, Longworth, & Arcelus, 2016). In light of the positive effects of gender 
affirmative interventions, there is a need for innovative strategies to address unmet need and to 
improve access to gender affirming treatments (Reisner et al., 2016).  
 
Health services for transgender people are guided by the World Professional Association for 
Transgender Health Standards of Care, 7th edition (SOC-7; Coleman et al., 2012). The SOC-7 describes 
the need to gather the following information as part of the assessment process: assessment of gender 
identity and gender dysphoria, history and development of gender dysphoric feelings, the impact of 
stigma attached to gender diversity on mental health, and the availability of support from family, 
friends, and peers (Coleman et al., 2012). Possibly due to the lack of empirical evidence regarding the 
assessment process, the SOC-7 does not provide guidance on the number of appointments the 
assessment process should be made up of and/or the number of clinicians that should be involved in 
the assessment process. As a consequence, there is not a standardised procedure that outlines the 
process of assessing a person who has been referred to a transgender health service and therefore is 
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great variation in assessment processes followed among services worldwide. 
As in many European countries, in the United Kingdom (UK) health services, including those for 
transgender people, are state funded. Currently there are seven transgender health services for 
people 18 years and older in the UK. Recently, these seven services have experienced an increase in 
demand. For example, the Nottingham Centre of Transgender Health, a nationally commissioned 
centre that offers care and treatment to people living in England and Wales, received 1030 referrals 
in 2016 which was double the number of referrals in 2015 (n=530) and dramatically more than in 2014 
(n=230) and 2013 (n=120). This increase in demand is not unique to this centre as a similar pattern 
has been describes by other centres within and outside the UK (de Vries et al., 2015; House of 
Commons., 2016). As a consequence of the increase in referral rates, extremely long waiting times to 
access state funding transgender health services in the UK have been experienced by many. Currently 
within the UK there are more than 5000 people waiting to be assessed with the average waiting times 
being over 2 years.  
 
Currently the assessment process offered at most transgender health services within England and 
Wales takes place over at least two appointments and involves two independent professionals.  As 
part of the assessment process, mental health needs are considered but these would not usually 
prevent a recommendation for gender affirmative treatment (SOC-7; Coleman et al., 2012). Gender 
identity is also assessed – this being a psychological identification of oneself or the internal sense of 
being in relation to gender. How people feel about their gender is, of course, very personal (Bouman 
& Arcelus, 2017) and only the individual truly knows how they feel about their gender (Coleman et al., 
2012). In view of this, assessing an individual’s gender identity may be unnecessary as they are in the 
best position to identify their gender. On the other hand, it is important to gather a gender history to 
exclude the possibility of major mental illnesses that may be presenting as gender dysphoria, albeit 
uncommon. For instance, a patient with Schizophrenia may hold delusional beliefs about their gender 
and body, which without exploration may be mistreated as gender dysphoria. It is also important that 
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the stability of gender identity and expression is ascertained due to the irreversibility of physical 
gender affirming interventions. In light of this, state funded transgender health services argue that 
there is benefit from a decision making process regarding these interventions that involves more than 
one clinician, despite there being a lack of direct evidence to support that this is best practice.  
 
Due to the lack of studies investigating the outcome of assessments at transgender health services, 
there is only a very rough consensus between clinicians and transgender health services as to what 
the most appropriate, effective and efficient process should be. Clinical practice should always be 
informed by empirical evidence (e.g., Sackett, Rosenberg, Gray, Haynes & Richardson, 1996) and 
therefore more research is warrant in exploring the best practice regarding assessment at transgender 
health services. This research should begin by investigating what the outcome of the current 
assessment process is. Such knowledge will inform initiatives to facilitate with improving and 
standardising the assessment process at transgender health services. In view of this, the main 
objective of this study is to investigate the outcome of the assessment process at a large national 
transgender health service in the UK. The study has several specific aims: First, to describe the 
different recommendations made by clinicians following assessment. Second, to compare patients 
who had and had not been recommended for the treatment programme on pre-assessment variables. 
Lastly, the study will investigate the levels of agreement between the two clinicians involved in the 
assessment process in order to investigate whether a second clinician aids the assessment outcome.  
 
 
 
 
 
Method 
Recruitment and participants  
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The study took place at the Nottingham Centre for Transgender Health within the National Health 
Service (NHS) in the United Kingdom. This is one of the largest clinics of its kind in Europe and receives 
more than 1000 referrals a year from people living in England and Wales. As per other UK services, 
referrals to the service are received mainly from primary care as well as secondary care. People cannot 
self-refer to this service. The routine assessment process consists of two separate appointments with 
two independent senior clinicians of 90 minutes each and a third appointment involving both 
clinicians, plus the individual being assessed. A significant other can be invited by the patient into the 
third appointment. There is usually a gap of 3 months between each assessment appointment. Due 
to capacity issues, patients can expect to wait approximately 2 years after the referral for the 
assessment process to begin, which is clearly unacceptable. The service accepts referrals of people 
aged 17 and over with a number of referrals being transferred from the NHS Gender Identity 
Development Service (the child and adolescent service) in London or Leeds.  Following the assessment, 
a decision is made as to whether the individual is ready and suitable to enter into the treatment 
programme (e.g., prescription of cross-sex hormone treatment). In order for transgender people to 
be accepted into the programme, it is usual for people to amend most of their legal documentation, 
including changing their name, which is a straight forward process in the UK. Aside from the 
assessment considerations detailed above, if there are no physical contraindications patients who 
wish to, will be prescribed cross-sex hormone treatment. Following a minimum of 6 months of living 
in their gender role, transgender males can then be considered for chest reconstructive surgery. 
Transgender males and females wishing to undergo genital surgery will usually live in their gender role 
for a minimum of one year and will usually have taken hormones during that time.  
 
Procedure 
For the first aim of the study, the clinical notes of all patients assessed at the centre during a two-year 
period (2014-2016) were examined. The outcome of the assessment was coded into two main groups: 
1) immediate recommendation to enter into treatment programme (or direct access to treatment- 
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DAT), or; 2) not recommended to enter into treatment programme (no direct access to treatment- 
NDAT). For the second aim, socio-demographic characteristics, including age and assigned sex as well 
as transitional status pre-assessment (coming out to others, name change, social gender role 
transition) was collected and both groups (DTA and NDTA) were compared on these variables. For the 
last aim, a sample of randomly selected active case-notes was examined (n-200). The 
recommendations made by the first and second assessor in each case were coded into the same two 
categories used in the first aim (DAT and NDAT). Where disagreement between assessors in the 
outcome recommended was identified, factors (socio-demographics) associated with disagreement 
were explored. These factors included age at the time of referral and at assessments, ethnic origin, 
assigned sex, and gender identity. 
 
The study was a part of a longitudinal study, which received ethical approval from the NHS Ethics 
committee and from the Research and Development Department from the Nottinghamshire 
Healthcare NHS Foundation Trust in line with Health Research Authority guidance (HRA, 2013). 
 
Data analysis 
All quantitative data analyses were performed using SPSS 22 (IBM, 2013). First, descriptive statistics 
were examined. Data were positively skewed in both groups (DAT and NDAT) and non-normally 
distributed, as demonstrated by significant (p=.002) Kolmogorov-Smirnov tests. Therefore, non-
parametric tests were selected. For comparison between groups, Mann-Whitney U tests and Chi-
square tests were conducted. The level of significance used was p < 0.05. 
 
Results 
Aim 1: outcome of the assessment process  
During the studied period a total of 617 people completed their assessment at the service. Following 
assessment 380 (61.6%) were recommended direct access to hormone treatment (DAT). A total of 237 
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(38.4%) people were not recommended direct access to hormone treatment (NDAT). In the majority 
of the cases where treatment was not initiated (or immediately initiated) the reasons were related to 
requiring a longer assessment process (n= 97, 40.9% of NDAT), not providing evidence of a social 
gender role transition, including change of name (n=52, 53.6% of the group requiring longer 
assessment). In 11 (4.6%) cases, psychotherapy was recommended, while 12 (5.1%) people did not 
attend the second appointment and therefore were discharged from the service. For nearly 40% of 
the cases (n=93, 39.2%) medical transition was not felt to be appropriate due to personal factors (such 
as non-acceptance from partners and complexities surrounding this) and asked to be discharged from 
the service. Following assessment, 24 (10.1%) of the NDAT group were unclear about their gender and 
felt that transition was not necessary.  
 
Aim 2: comparing DAT to NDAT on pre-assessment socio-demographic variables  
The mean age for the whole group was 30.65 years (SD=14.03) with a minimum of 17 years and a 
maximum of 79. People not offered direct access to treatment appeared older (mean=31.65, SD= 
14.20) than people in the DAT group (mean=30.02 SD=13.90) however, the difference between groups 
was not significant (U=40944.00, z=-1.90, p=.057). A Chi-square test indicated significant association 
between assigned gender and direct access to treatment with more people assigned male at birth 
than assigned female at birth being offered direct access to the treatment programme (DAT; see Table 
1). In the NDAT group there was bigger number of people who were described as a smoker; who had 
not come out as transgender; and who had not made a social gender role transition in comparison to 
the DAT group pre-assessment (see Table 1). Additionally, people who had taken hormones pre-
assessment were significantly more likely to be recommended for the initiation of gender affirming 
interventions after the assessment process than people who had not taken hormones pre-assessment 
(see Table 1). Information was not available for 4 cases.  
 
Insert Table 1 around here 
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Aim 3: Discordance between the outcome of first and second assessor for entry into the treatment 
programme 
Out of the 200 case notes reviewed, agreement between assessor 1 and 2 (3 months apart) was found 
in 88% (n= 176) of the cases. In most cases (n=23, 95.8%) disagreement between assessor 1 and 2 was 
present because in the first assessment appointment the patient had not made a social gender role 
transition (and therefore did not recommended initiation of gender affirmative treatments) but in the 
second appointment with assessor two, a social gender role transition had been made. There was only 
one case where the first assessor recommended treatment but not the second assessor. Of the 
patients with discordant assessment recommendations, the majority (80%) were people assigned 
male at birth and in both instances a difference in treatment recommendations were found for people 
assigned female at birth this was related to obtaining documents in the interim. No significant trends 
were identified in the other socio-demographic data collected. 
 
Discussion 
This study aimed to investigate the outcome of the assessment process at a large national transgender 
health service in the UK and explore factors associated with people who were and were not 
recommended for the treatment programme. It was hoped that obtaining this information would 
inform the development of initiatives to facilitate with improving the assessment process (i.e., making 
it more efficient) as well as standardising the assessment process. The findings from this study 
demonstrated that more than half of the people assessed at this large national centre in the UK were 
recommended for treatment following routine assessment. The reasons for why treatment was not 
recommended were associated with the person not changing their legal documents, including name. 
Socially transitioning before physical gender affirming interventions is not mandatory in some 
transgender health services and not a requirement stipulated by the SOC-7 (Coleman et al., 2012). 
However, clinicians at the Nottingham Centre for Transgender Health (and in many other centres in 
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the UK) feel that it is important that people first make a social gender role transition to determine 
how this will be orchestrated and be accepted by the person themselves and others around them, 
prior to irreversible interventions being offered. This requirement once again lacks evidence and 
future studies should investigate the role of socially transitioning prior to cross-sex hormones has on 
outcomes.  
 
The current study also demonstrated that the in the majority of the cases both assessors involved in 
the assessment process agreed regarding recommendation for physical gender affirming 
interventions. Due to the high level of agreement, the need for two different assessors in the 
assessment process should be questioned. Having one assessor would facilitate with decreasing 
waiting times at transgender health services. Once again the involvement of two different assessors 
for interventions other than genital surgery is not evidence based and not a requirement stipulated 
by SOC-7 (Coleman et al., 2012). At the Nottingham Centre for Transgender Health, levels of expertise 
and seniority at this centre is very high which may result in higher levels of agreements between 
assessors; and therefore transgender health services with more junior staff may have different 
findings. In these circumstances, having two assessors may be appropriate although further research 
is required.  
 
To facilitate with improving the assessment process at transgender health services, being able to 
differentiate between people who are ready for hormone treatment from those who are not, is 
important. So far this study is able to demonstrate that people who have socially transitioned, do not 
smoke, are on cross sex hormones, are older, and are assigned male at birth (mainly related to social 
transition) pre-assessment are more likely to be recommended for the treatment programme 
following the assessment process than people who have not socially transition, smoke, have not taken 
cross-sex hormones, are younger and assigned female at birth pre-assessment. Services where social 
transitioning pre-treatment is not a requirement may have an even higher number of people entering 
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the treatment programme for initiation of cross-sex hormones. Future factors such as the role of social 
support (Bouman, Davey, Meyer, Witcomb, & Arcelus, 2016; Davey, Bouman, Arcelus, & Meyer, 2014); 
age (Arcelus et al., 2016); and certain characteristics such as features of autistic spectrum found to be 
high among this population (Glidden, Bouman, Jones, & Arcelus, 2016) could also be considered in 
future studies. Future studies may also investigate the role of assessment in reaching diagnostic 
criteria in view of the future ICD-11 diagnosis (Beek et al., 2016). 
 
The majority of the disagreement between assessors in recommendation for the treatment 
programme found in the current study could be influenced by temporal factors, as opposed to the 
fact that assessments were undertaken separately by two senior clinicians. It may well be that the first 
assessment acted as a ‘spur’ to act (i.e., make a social gender role transition); but given the nature of 
the pressures on the service, thought must be given to the assessment process with a view to 
increasing patient throughput, but without increasing the risk of harm to patients by recommending 
inappropriate interventions. Indeed, it is worth considering that as the Nottingham Centre for 
Transgender Health is an NHS (taxpayer funded) service, there is an expectation that the treatment 
bring with it significant benefit - rather than simply the lack of harm which may be the basis of some 
systems where the patient themselves pays for treatment. Further, long-term outcomes from gender 
affirming treatment has not been well studied and has mainly focussed on mental health (e.g., Davis 
& Meier et al., 2014; De Cuypere, Elaut, Heylens & Monstrey, 2006; Heylens, Verroken, De Cock, 
T’Sjoen & De Cuypere, 2014). Rates of ‘regrets’ with transition indicated by a wish to de-transition 
back to assigned gender are rare and there is no evidence that a prolonged assessment process 
improves outcome (regarding mental health) or reduces regret (e.g., Lawrence, 2003). Although the 
results of the study may not be generalizable to other international centres, especially those which 
are not taxpayer funded, questioning the assessment process and the role of the assessors in the field 
of transgender health is important.  The role of assessment, as well as investigating ways of increasing 
the efficiency of the process, needs to be examined. 
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Table 1: Chi-square test comparing people who were (n=380) and were not (n=237) recommended 
for the treatment programme after the assessment process on pre-assessment socio-demographic 
variables 
 DAT patients 
(n=380) 
NDAT patients 
(n=237) 
χ2 
 Sample size (%)  
Mean (SD) age 30.02 (13.90) 31.65 (14.20)  
Assigned female 167 (74.22%) 58 (25.77%) 
23.89*** 
Assigned male 213 (54.33%) 179 (45.66%) 
Smoker 44 (49.43%) 45 (50.56%) 
6.49** 
Non-smoker 336 (63.63%) 192 (36.36%) 
Hormones  130 (81.25%) 30 (18.75%) 
41.42*** 
No hormones 245 (54.68%) 203 (45.31%) 
Come out as transgender 324 (66.52%) 163 (33.47%) 
23.85*** 
Not come out as transgender 56 (43.07%) 74 (56.92%) 
Social gender role transition  218 (77.30%) 64 (22.69%) 
54.23*** 
Not made a social gender role transition  162 (48.35%) 173 (51.64%) 
*p<0.05, **p<0.01, ***p<0.001; DAT=Direct access to hormone treatment, NDAT= No direct access 
to hormone treatment  
